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Abstract: Eszopiclone is the S-isomer of racemic zopiclone, a cyclopyrrolone with sedative-
hypnotic activity that has been available in Europe, Canada, and Latin America since 1987. 
Eszopiclone acts by binding to the GABAA receptor. In contrast to the benzodiazepine (BZD) 
hypnotics, eszopiclone has more selectivity for certain subunits of the GABAA receptor. Oral 
eszopiclone is rapidly absorbed and extensively distributed to body tissues including the brain. 
Peak plasma concentrations are attained 1.0–1.6 hours after a 3 mg dose, while the mean 
elimination half-life is 6 hours. The half-life increases with age to about 9.0 hours in patients 
65 years or older. Eszopiclone’s pharmacokinetic (PK) proﬁ  le is not substantially modiﬁ  ed in 
patients suffering from renal failure or mild-to-moderate hepatic impairment, although patients 
with severe hepatic insufﬁ  ciency should have a reduced dose. The subjective perception of 
improved sleep following eszopiclone 2 or 3 mg treatment has been demonstrated in random-
ized, double-blind, placebo-controlled studies of up to 6 months’ duration. In these studies the 
drug signiﬁ  cantly reduced sleep onset latency (SOL), the number of awakenings, and wake time 
after sleep onset (WASO) whereas total sleep time (TST) and quality of sleep were increased 
in non-elderly and elderly subjects. Sleep laboratory studies of the effects of eszopiclone have 
conﬁ  rmed the drug’s clinical efﬁ  cacy in subjects with chronic primary insomnia. Eszopiclone, 
unlike BZD hypnotics, does not signiﬁ  cantly alter values corresponding to slow wave sleep 
(SWS or stages 3 and 4) and rapid eye movement (REM) sleep. Rebound insomnia following 
withdrawal of eszopiclone has been examined in only one study. Discontinuation of the active 
treatment with 2 mg was followed by rebound insomnia in non-elderly subjects. Three-mg doses 
of eszopiclone administered for a period of up to 12 months was associated with a sustained 
beneﬁ  cial effect on sleep induction and maintenance, with no occurrence of tolerance. The 
most common side-effects were unpleasant or bitter taste, headache, dyspepsia, pain, diarrhea, 
dry mouth, upper respiratory infection, urinary tract infection, dizziness, and accidental injury. 
New adverse events (withdrawal symptoms) including anxiety, abnormal dreams, hyperesthesia, 
nausea, and upset stomach were recorded in one study on the days following eszopiclone 2 or 3 
mg discontinuation. Although dependence and abuse potential have not been formally assessed, 
unpublished data show that eszopiclone at doses of 6 and 12 mg produces euphoria effects similar 
to those of diazepam 20 mg in BZD drug addicts. In conclusion, available evidence tends to 
indicate that eszopiclone is effective and safe for the treatment of chronic primary insomnia in 
non-elderly and elderly subjects. Tolerance did not occur during active drug administration for 
a 12-month period. Thus eszopiclone can be efﬁ  cacious not only during short- and intermediate-
term administration but also in patients requiring prolonged regular drug usage.
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Insomnia: diagnostic criteria
Insomnia is a complaint characterized by difﬁ  culty falling asleep (sleep latency of more 
than 30 minutes), insufﬁ  cient sleep (total sleep time (TST) of less that 5.5–6 hours), 
numerous nocturnal awakenings, an early morning awakening with inability to resume 
sleep, or nonrestorative sleep. Common daytime symptoms occurring secondary to 
the complaint of insomnia include somnolence, fatigue, irritability, and difﬁ  culty in 
concentrating or performing every day tasks. In addition, subjects with a diagnosis of Neuropsychiatric Disease and Treatment 2007:3(4) 442
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insomnia are at risk of injury, drowsiness while driving, and 
illness. The objective measures for insomnia (sleep latency 
and total sleep time) correlate poorly with the subjective 
complaint of insomnia. Thus, when considering the results 
of clinical trials that have used self reports it should be 
taken into consideration that subjects with insomnia tend to 
overestimate the degree of their sleep difﬁ  culty, ie, they tend 
to report shorter sleep times and longer times to sleep onset 
compared with subjects assessed in the sleep laboratory. In 
addition, the reliability and the interpretation of results can be 
affected by the subject’s estimates of hypnotic drug effects, 
which are quite variable because of the inﬂ  uence of recent as 
well as past experiences with other sleep medications.
The International Classiﬁ  cation of Sleep Disorders (2005) 
uses the severity of impairment as a guide to be applied in 
conjunction with consideration of the patient’s clinical status. 
Mild insomnia refers to an almost nightly complaint of an 
insufﬁ  cient amount of sleep or not feeling rested after the 
habitual sleep episode. Moderate and severe insomnia refer 
to the nightly experience of an insufﬁ  cient amount of sleep 
or of not feeling rested despite having spent a normal amount 
of time in bed, accompanied by impairment of social and/or 
occupational functioning.
The duration of insomnia has been considered an important 
guide to its evaluation and treatment. Individuals with transient 
insomnia are normal sleepers who experience an acute stress 
for a few days (eg, air travel to a new time zone, hospitaliza-
tion for elective surgery, changing work shifts, or sleeping in 
an unfamiliar environment) which disrupts their sleep. Short-
term insomnia is usually associated with situational stress, 
often related to work or family life or serious medical illness. 
This type of insomnia may last up to 3 weeks. However, in 
some cases short-term insomnia may progress into a chronic 
condition. Conventionally, long-term or chronic insomnia has 
been considered to be that which lasts for at least 21–30 nights. 
Usually, it persists for months or years, and its onset may or 
may not be associated with an identiﬁ  able stressor. Insomnia 
can be considered also primary or secondary. The diagnosis 
of primary insomnia (APA 1994) has been considered to be 
chronic insomnia occurring in patients without sleep, medical, 
substance abuse, or psychiatric diagnoses causing those symp-
toms. However, this diagnosis has been deﬁ  ned differently 
in different studies. In the eszopiclone studies, the patients 
had long-term insomnia (>3 months), with >45 min time to 
sleep onset and <6.5 hours per night, stable medical status, no 
psychiatric diagnoses, and controlled caffeine and nicotine 
use. The current diagnostic codes included in the International 
Classiﬁ  cation of Sleep Disorders (2005) comprise four primary 
insomnia diagnoses: adjustment insomnia, psychophysiologi-
cal insomnia, paradoxical insomnia, and idiopathic insomnia. 
Secondary insomnia can be precipitated or aggravated by 
another sleep disorder, a disturbance of circadian rhythm, a 
neurological or psychiatric disease, a general medical condi-
tion, or the direct effects of a medication or a substance of 
abuse. In sleep disorders centers, about 20% of all insomniacs 
are diagnosed with primary insomnia and about 44% of cases 
with secondary insomnia, the most frequent form of insomnia 
that is predominantly associated with psychiatric disorders (eg, 
mood disorders) (Buysse et al 1994; Coleman et al 1981).
Insomnia is a multidimensional disorder and may have 
varied underlying pathology. Any strategy to its effective 
management should appropriately combine both pharma-
cological and a non-pharmacological measures and depends 
on the duration, severity, and complexity of the underlying 
pathology. In practice, pharmacological treatment of insom-
nia predominates over psychotherapy and other treatment 
methods. In patients with chronic insomnia combined with 
coexisting psychiatric, neurologic, or medical conditions; 
the underlying disorder needs to be assessed and treated 
appropriately (Lichstein et al 2006).
Several classes of medication have been prescribed 
as hypnotics over the years. The benzodiazepine 
receptor agonists (BzRAs) were introduced in the 1970s, 
and rapidly increased in popularity because of their efﬁ  cacy 
and relative safety compared with the barbiturates, 
carbamates, chloral derivatives, and methaqualone (Harvey 
1980). However, the risk of dependence, the occurrence of 
rebound insomnia following the withdrawal of short- and 
intermediate-acting derivatives, and the loss of efﬁ  cacy 
after a few weeks of treatment led to a decrease in their use 
in recent years. The reduction in BZD hypnotics use has 
coincided with the introduction of a structurally dissimilar 
group of non-benzodiazepine (non-BZD) derivatives, such 
as the cyclopyrrolone agents zopiclone and eszopiclone, 
the imidazopyridine derivative zolpidem, and the pyrazo-
lopyrimidine compound zaleplon (Monti 2004; Monti and 
Monti 2006). Such an approach to new drug developments 
in the central nervous system (CNS) sector unequivocally 
must demonstrate: (a) a gradually improved efﬁ  cacy and 
markedly reduced half-life for the newest drugs; (b) greatly 
enhanced safety and side-effect proﬁ  le; and (c) the search 
for other structurally dissimilar groups (eg, cyclopyrrolones, 
imidazopyridine, pyrazolopyrimidine, and also melatonin 
receptor agonists [MelRAs; eg, ramelteon]) possessing 
varied mechanisms of action with improved clinical outcome 
(Ebert et al 2006).Neuropsychiatric Disease and Treatment 2007:3(4) 443
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Preclinical pharmacology 
of the cyclopyrrolone derivatives
Zopiclone {[6-(5-chloro-2-pyridyl)-6, 7-dihidro-7-oxo-5H-
pyrrolo [3,4-b]pyrazin-5-yl]4-methyl-1-piperazine-carboxylate} 
was synthesized by Rhône-Poulenc Recherches in the early 
1970s (Bardone et al 1978), and its therapeutic activity as 
an hypnotic was recognized soon after (Duriez et al 1979; 
Nicholson and Stone 1983).
Eszopiclone, the dextrorotatory enantiomer of racemic 
zopiclone, has a single chiral center with an S(+)-conﬁ  gura-
tion (Najib 2006). 
Preclinical studies have shown zopiclone to exhibit 
sedative-hypnotic, anticonvulsant, myorelaxant, antiaggres-
sive, and anticonﬂ  ict activities (Joulou et al 1983, 1985). 
With regard to the sedative-hypnotic activity, zopiclone 
decreases locomotor activity, disrupts rotarod performance, 
reduces waking, and increases SWS in the rat (Joulou et al 
1985; Ueki et al 1987; Carlson et al 2001). Spectral analysis 
of the cortical EEG after zopiclone administration has shown 
an increase of power density in the 2.0–4.0 Hz (delta), and 
the 12.0–16.0 Hz (beta) bands in the rat (Depoortere et al 
1986). Eszopiclone shares the sedative-hypnotic properties 
of zopiclone whereas the (R)-enantiomer has no hypnotic 
activity (Carlson et al 2001).
Mechanism of action of zopiclone 
and eszopiclone
γ-Amino butyric acid (GABA) is the most important inhibi-
tory neurotransmitter in the mammalian brain and localizes 
to approximately 30% of CNS synapses. This inhibitory 
neurotransmitter is of particular interest because most thera-
peutically useful hypnotic drugs work by selectively affecting 
GABA receptors.
A number of classes of GABA receptors including 
the GABAA, GABAB, and GABAC receptors have been 
characterized in the CNS of several species, including man 
(Korpi 2006). The distribution of GABA receptor types 
varies throughout the CNS. The GABAA receptor is the 
site of action of several hypnotic agents including BZDs, 
cyclopyrrolones (zopiclone, eszopiclone), imidazopyridine 
(zolpidem), and pyrazolopyrimidine (zaleplon) deriva-
tives. These different classes of hypnotic drugs modulate 
GABAergic function through different GABAA receptor sub-
types, deﬁ  ned by the subunits that participate in the receptor 
assembly. Most GABAA receptors consist of α, β, and γ 
subunits which contain multiple isoforms or variants: α1–α6, 
β1–β3, and γ1–γ3. Zolpidem and zaleplon preferentially bind 
α1-containing subtypes (Ator and McCann 2005). On the 
other hand, BZDs, zopiclone, and eszopiclone bind at all 
GABAA subtypes. Notwithstanding this, the mechanism of 
action of the cyclopyrrolone derivatives may not be identical 
to that of the BZD hypnotics. In this respect it has been pro-
posed that the cyclopyrrolones might have more selectivity 
for certain subunits of the GABAA receptor (Double 1999; 
Drover 2004; Sanger 2004). This could tentatively explain 
the difference in effects on sleep architecture and the lower 
incidence of adverse events, including rebound insomnia 
and withdrawal phenomena, during the administration of 
zopiclone and eszopiclone to patients with insomnia.
Pharmacokinetics of eszopiclone 
in healthy adults and in populations 
at risk
The pharmacokinetics of the (S)-isomer of zopiclone has 
been investigated in healthy adults and in populations 
at risk (Table 1). Eszopiclone is rapidly absorbed and 
extensively distributed to body tissues including the brain. 
It is weakly bound to plasma protein (52%–59%). Peak 
plasma concentrations (tmax) are attained 1.0–1.6 hours 
after a single therapeutic dose of 3 mg, and the terminal-
phase elimination half-life (t½) amounts to approximately 
6.0 hours. Eszopiclone is metabolized in the liver to form 
(S)-N-desmethyl zopiclone and (S)-zopiclone-N-oxide 
(Fernández et al 1993; Sanger 2004). Racemic zopiclone 
is also extensively transformed in the liver to the N-oxide 
(less active) and the N-desmethyl (inactive) derivative; 
the N-oxide metabolite contributes to the hypnotic effect 
of zopiclone (Noble et al 1998). Although studies of the 
clinical effect of the N-oxide derivative of eszopiclone 
are not complete, the metabolite would be expected to 
contribute to the sleep-inducing and maintenance effect of 
the parent drug. In vitro studies have shown that CYP3A4 
and CYP2E1 are the major enzymes involved in eszopiclone 
metabolism. CYP2C8 contributes also to (S)-zopiclone-
N-oxide formation (Becquemont et al 1999). After oral 
administration, eszopiclone is predominantly excreted in 
the urine, primarily as metabolites. Less than 10% of the 
compound is excreted in the urine as parent drug.
The metabolic clearance of eszopiclone is reduced in 
elderly subjects, aged 65 years and older, resulting in increases 
in Cmax and t½, the latter amounting to approximately 9.0 hours 
(Sanger 2004). The removal of eszopiclone from the body is 
also impaired in patients with severe hepatic insufﬁ  ciency, 
thus requiring dose reduction. On the other hand, no dose Neuropsychiatric Disease and Treatment 2007:3(4) 444
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adjustment is necessary for patients with mild-to-moderate he-
patic impairment. The clearance of eszopiclone is not altered 
in patients with mild, moderate, or severe renal insufﬁ  ciency. 
Thus, no dose adjustment is required in patients with renal 
failure (Najib 2006).
In summary, based on the available evidence, a reduction 
in the initial dose of eszopiclone is recommended in elderly 
subjects and patients with severe hepatic impairment.
Evidence for eszopiclone hypnotic 
activity
Eszopiclone was approved by the US Food and Drug 
Administration (FDA) in 2004 for the treatment of insomnia, 
the ﬁ  rst insomnia treatment medication to be approved 
without the short-term indication associated with all previ-
ous hypnotics.
Two principal techniques have been employed to 
evaluate the effects of eszopiclone on sleep in humans. One 
of the techniques makes use of subjective evaluation based 
on questionnaires (clinical approach) whereas the other 
approach involves the utilization of the sleep laboratory. 
In some studies, the efﬁ  cacy has been assessed using both 
polysomnography (PSG) and subjective self reports (Zammit 
et al 2004; Rosenberg et al 2005; Roth et al 2005; McCall 
et al 2006; Soares et al 2006).
The efﬁ  cacy endpoints included sleep onset latency 
(SOL), wake time after sleep onset (WASO), total sleep time 
(TST), number of awakenings, sleep efﬁ  ciency (SE), quality 
of sleep, daytime ability to function, daytime alertness, and 
sense of physical well-being (Zammit et al 2004; Rosenberg 
et al 2005). 
Various populations were included in the studies that 
assessed the efﬁ  cacy and safety of eszopiclone: healthy 
volunteers, non-elderly, and elderly subjects with chronic 
primary insomnia, and patients with major depressive 
disorder (MDD) and comorbid insomnia (Rosenberg et al 
2005; Zammit et al 2006). However, as discussed above, 
to date much of the published information on the effect of 
Table 1 Pharmacokinetic parameters for eszopiclone in healthy adults and populations at risk
Non-elderly subjects(1)
rapidly absorbed (data not available for eszopiclone; racemic zopiclone: 95% of absorption with a bioavailability of 80%).
Cmax
(2): 87.3 ng/mL
Tmax
(3): 1.0–1.6 hours
AUC(4): 691.3 mg/mL
weakly bound to plasma protein (52%–59%)
t½
(5): 6.0 hours
Vd(6): 98.6 L
effect of high-fat meal: reduces Cmax by 21%, and delays Tmax by approximately 1 hour; t½ remains unchanged.
metabolized by oxidation and demethylation to (S)-zopiclone-N-oxide and (S)-N- desmethyl zopiclone. CYP3A4 and CYP2E1 enzymes are involved in  
the metabolism of eszopiclone.
excreted in the urine primarily as metabolites; less than 10% of the orally administered 
eszopiclone is excreted as parent drug.
Elderly subjects
the metabolism is reduced resulting in increased AUC (41%) and prolonged t½ to approximately 9 hours.
Hepatic impairment
the AUC was increased 2-fold in patients with severe impairment (alcoholic cirrhosis); Cmax and Tmax remained unchanged.
Renal impairment
reductions in clearance in patients with mild, moderate, or severe renal impairment were not signiﬁ  cant.
Women who are breast-feeding
eszopiclone is secreted into breast milk.
Distribution to salivary glands
the data on eszopiclone distribution to salivary glands are not complete. Following  racemic zopiclone administration bitter taste occurs when saliva  
concentrations exceed 50 μg/L. 
From Fernández et al (1993, 1995); Noble et al (1998); Lunesta [Prescribing information] 2005.
(1)Single doses of up to 7.5 mg and once-daily administration of 1.0, 3.0, and 6.0 mg for 7 days.
(2)Cmax: maximum plasma concentration.
(3)Tmax: time to peak concentration.
(4)AUC: area under the concentration curve.
(5)t½: mean elimination half-life.
(6)Vd: volume of distribution.Neuropsychiatric Disease and Treatment 2007:3(4) 445
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eszopiclone on sleep variables has been gathered from studies 
that included subjects with chronic primary insomnia. 
Taking into consideration that long-term hypnotic medi-
cation may be beneﬁ  cial in patients with chronic insomnia, 
the efﬁ  cacy and safety of eszopiclone have been assessed 
following 6 and 12 months of treatment in adult subjects 
with chronic primary insomnia.
Transient insomnia
Previous studies have shown that the ﬁ  rst night in a sleep 
laboratory can be used as an effective model of transient 
insomnia (Koshorek et al 1988; Monti et al 1993). In 
this respect, Rosenberg et al (2005) assessed the effect of 
eszopiclone on transient insomnia in healthy adults who 
slept in an unfamiliar environment (sleep laboratory) for 
one night (Table 2a). The study included 436 healthy 
adults with no sleep laboratory experience. The subjects 
were randomly assigned to one of four treatment groups 
(placebo, eszopiclone 1, 2, 3, or 3.5 mg), and spent one night 
in the sleep laboratory. They remained in bed for 8 hours 
with standard PSG recordings. In the morning the subjects 
were interviewed about the efﬁ  cacy and safety of treatment. 
In addition, the digit symbol substitution test (DSST) was 
administered to objectively determine residual next-day 
psychomotor drug effects.
Compared with placebo, stage 2 sleep latency and 
the number of awakenings were signiﬁ  cantly reduced by 
eszopiclone 2–3.5 mg and 3–3.5 mg, respectively. More-
over, all doses of eszopiclone induced a signiﬁ  cant reduc-
tion of WASO and an increase of sleep efﬁ  ciency. Stage 1 
sleep and the amount of REM sleep as a percentage of TST 
showed a signiﬁ  cant decrease after the 3.5 mg dose of the 
cyclopyrrolone derivative. On the other hand, eszopiclone 
did not alter the percentage of stage 3 and stage 4 sleep.
Eszopiclone signiﬁ  cantly improved the self-reported 
ease of getting to sleep, TST, and quality of sleep. There 
was also a reduction in the subjects’ reports of the number 
of awakenings and WASO. 
There were no signiﬁ  cant decrements in the next-morning 
DSST scores across any treatment groups. Moreover, the 
experimental subjects were not more or less sleepier than 
those taking the placebo. Despite reports of side-effects 
of unpleasant taste, somnolence, headache, and dizziness, 
eszopiclone was generally well tolerated. 
As pointed out by the authors, no studies have been 
carried out on the effect of eszopiclone in a true transient 
insomnia population. However, this is not the case with 
zopiclone. Momose (1982) examined the efficacy of 
zopiclone on the preoperative night’s sleep of patients who 
were scheduled to undergo a surgical operation. The patients 
were randomly assigned to one of three treatment groups of 
59 patients (placebo, zopiclone 7.5, or 10 mg). The treatment 
was administered double-blind at 21.00 h the night preced-
ing the day of operation. Subjective efﬁ  cacy measures were 
recorded and rated by a physician on the day of operation. 
Zopiclone 7.5 or 10 mg proved superior to placebo on sleep 
induction, number of nocturnal awakenings, duration and 
quality of sleep, and state on awakening the next morning. 
The cyclopyrrolone derivative was assessed as very useful 
or useful by 75% of patients. The commonest side-effects 
were bitter taste, dizziness, and heaviness.
In a study by Moon et al (1990) zopiclone 7.5 mg or 
placebo was given to 12 healthy young male subjects working 
12-hour shifts in radar installations. The subjects received 
zopiclone 7.5 mg or placebo at bed-time during each of the 
4-day shift cycles with a 4-day rest period as a washout 
phase. Zopiclone signiﬁ  cantly improved night-time sleep 
quality (LSEQ; Leeds Sleep Evaluation Questionnaire) of 
subjects before the day shifts. Day-time sleep before night 
shifts showed a non-signiﬁ  cant trend in the direction of 
improvements, which could have been related to the particular 
work schedule of the volunteers. There were no signiﬁ  cant 
effects on any of the measures of performance (assessed by 
critical ﬂ  icker fusion test, choice reaction time, and DSST) 
or mood (assessed by linear visual analogue scales).
It can be concluded that racemic zopiclone improves 
sleep in true transient insomnia populations, and that a similar 
outcome can be expected during eszopiclone administration.
Chronic primary insomnia 
in non-elderly subjects
Zammit et al (2004) evaluated the effects of 6 weeks of 
eszopiclone treatment in insomniac subjects with respect 
to effects on nocturnal sleep, rebound insomnia, and tol-
erance. The study involved 308 subjects with moderate 
chronic primary insomnia (mean values = sleep latency: 33.0 
min; WASO: 50.0 min; number of awakenings: 6.6; sleep 
efﬁ  ciency: 83.5%). Subjects were randomly assigned to one 
of three treatment groups: placebo (n = 99); eszopiclone 
2 mg (n = 104), or eszopiclone 3 mg (n = 105). The period 
of treatment involved 44 nights, including 4 nights in the 
sleep laboratory. On the ﬁ  rst night a placebo was adminis-
tered single-blind, and sleep was recorded and quantiﬁ  ed so 
that the extent and nature of the sleep disturbance could be 
estimated. The second night (ﬁ  rst double-blind treatment 
night) was used for analysis of short-term effectiveness, night Neuropsychiatric Disease and Treatment 2007:3(4) 446
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Table 2a Effects of eszopiclone on sleep parameters in normal subjects with transient insomnia, and non-elderly and elderly patients 
with chronic primary insomnia
  Rosenberg et al (2005)  Zammit et al (2004)
Study design  randomized double-blind  randomized double-blind
  placebo-controlled multicenter  placebo-controlled multicenter
Number of patients  436 healthy adults  308 (95% completed the study)
Mean age (years)  33.7 (range: 25–50)  39.8 (range: 21–64)
Diagnostic criteria  transient insomia (ﬁ  rst night effect)  DSM-IV criteria for primary insomnia
Number of drug evaluation night(s)  one night  44 nights
Dosage (mg)  placebo (n = 98);eszopiclone  placebo (n = 99); 
  1 mg (n = 47); 2 mg (n = 97);  eszopiclone 2 mg
  3 mg (n = 98); 3.5 mg (n = 96)  (n = 104); 3 mg
  (n  =  105)
Assessment of sleep  polysomnography  polysomnography:
  self-reports  nights 1, 15 and 29
    self-reports: nights 1, 15
  29  and  43/44
Objective sleep parameters
Sleep induction
NREM sleep latency (min)   decrease (2–3.5 mg)a  decrease (2–3 mg)a,d
Sleep maintenance
Number of awakenings  decrease (3–3.5 mg)a n.s.b,d
WASOe (min)  decrease (1–3.5 mg)a  decrease (3 mg)a,d
Total sleep time (min)  ---  ---
Sleep efﬁ  ciency (%)  increase (1–3.5 mg)a  increase (2–3 mg)a,d
Sleep architecture
Stage 1 sleep (min or %)  decrease (3.5 mg)a n.s.b,d
Stage 2 sleep (min or %)   increase (3.5 mg)a  increase (2–3 mg)a,d
Slow wave sleep (stage 3/4)
(min or %)  n.s.b n.s.b,d
REM latency (min)  ---  ---
REM sleep (min)  ---  n.s.b,d
REM sleep (% of TST)c  decrease (3.5 mg)a ---
Subjective sleep parameters
Sleep latency  decrease (1–3.5 mg)a  decrease (2–3 mg)a,d
Number of awakenings  decrease (1–3.5 mg)a ---
WASO  decrease (3–3.5 mg)a  decrease (3 mg)a,d
Total sleep time   increase (2–3.5 mg)a  increase (2–3 mg)a,d
Quality of sleep  increase (2–3.5 mg)a  increase (2–3 mg)a,d
Rebound insomnia  ---  present on the ﬁ  rst night after
    discontinuation of treatment with 
  2  mg  eszopiclone
Tolerance ---  absent
aSigniﬁ  cantly different from placebo (p < 0.05)
bn.s. = non-signiﬁ  cant
cTST = total sleep time
dAverage of nights 1, 15 and 29
eWASO = wake time after sleep onsetNeuropsychiatric Disease and Treatment 2007:3(4) 447
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Table 2b Effects of eszopiclone on sleep parameters in normal subjects with transient insomnia, and non-elderly and elderly subjects 
with chronic primary insomnia
  Krystal et al (2003)  Scharf et al (2005)  McCall et al (2006)
Study design  randomized  randomized  randomized
 double-blind  double-blind  double-blind
 placebo-controlled  placebo-controlled  placebo-controlled
Number of patients  788 (471 completed  231 (210 completed   264 (255 completed
  the study)  the study)  the study)
Mean age (years)  43.8 (range 21–69)  72.3 (range 64–85)  71.1
Diagnostic criteria  DSM-IV criteria for  DSM-IV criteria for  DSM-IV criteria for
  primary insomnia  primary insomnia  primary insomnia
Number of drug
evaluation nights  6 months  2 weeks  2 weeks
Dosage (mg)  placebo (n = 196);  placebo (n = 80);  placebo (n = 128);
  eszopiclone 3 mg   eszopiclone 1 mg  eszopiclone 2 mg
  (n = 595)  (n = 72); 2 mg   (n = 136)
    (n = 79)
Assessment of sleep  interactive voice   interactive voice   polysomnography:
  response system  response system  nights 1, 2, 13 and 
      14; patients reports:
      nights 1 to 14
Objective sleep parameters
Sleep induction
  NREM sleep latency
 (min)  ---  ---  decreasea
Sleep maintenance
  Number of awakenings  ---  ---  n.s.
 WASO  (min)  ---  ---  decreasea
  Total sleep time (min)  ---  ---  increasea
 Sleep  efﬁ  ciency (%)  ---  ---  increasea
Sleep architecture
  Stage 1 sleep (min or %)  ---  ---  n.s.
  Stage 2 sleep (min or %)  ---  ---  increasea
  Slow wave sleep 
  (stage 3/4) (min or %)   ---  ---  n.s.
  REM latency (min)  ---  ---  ---
  REM sleep (min)  ---  ---  n.s.
  REM sleep (% of TST)  ---  ---  increasea
Subjective sleep parameters
 Sleep  latency  decreasea  decrease (1–2 mg)a decreasea
  Number of awakenings  decreasea n.s.  decreasea
 WASO  decreasea  decrease (2 mg)a decreasea
  Total sleep time  increasea  increase (2 mg)a increasea
  Quality of sleep  increasea  increase (2 mg)a increasea
Rebound insomnia  ---  ---  ---
Tolerance absent  --- ---
aSigniﬁ  cantly different from placebo (p < 0.05)Neuropsychiatric Disease and Treatment 2007:3(4) 448
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15 to determine intermediate-term efﬁ  cacy, and night 29 for 
analysis of long-term effectiveness. Efﬁ  cacy was evaluated 
in addition to subject reports on nights 1, 15, 29, and 43/44. 
Subjects returned to the sleep laboratory on nights 45 and 46 
to assess the occurrence of rebound insomnia.
The effects of eszopiclone or a placebo are summarized in 
Table 2a. Stage 2 sleep latency showed a signiﬁ  cant decrease 
after either dose of eszopiclone relative to placebo. On the 
other hand, the number of nocturnal awakenings was not 
signiﬁ  cantly modiﬁ  ed by the hypnotic drug. The assessment 
of sleep continuity measures showed a signiﬁ  cant reduction 
of WASO after the 3 mg dose and an increase of SE after 
the 2- and 3 mg doses. 
During the ﬁ  rst withdrawal night WASO was signiﬁ  -
cantly increased and SE decreased relative to baseline in the 
eszopiclone 2 mg group. Changes tended to resolve by the 
second night after eszopiclone discontinuation. Sleep induc-
tion and maintenance did not deteriorate in the eszopiclone 
3 mg group during nights 45 and 46.
Tolerance was not observed after the 3 mg dose of the 
derivative. 
With respect to sleep architecture, the inferred increase 
of non-rapid eye movement (NREM) sleep was coupled with 
signiﬁ  cantly higher levels of stage 2. Stages 3 and 4 were not 
signiﬁ  cantly different between 2 mg and 3 mg eszopiclone 
and placebo. A similar outcome was observed in relation to 
time spent in REM sleep.
Subjective evaluation was correlated with the sleep 
laboratory ﬁ  ndings. Accordingly, eszopiclone 2 mg and 
3 mg improved subjective ratings of the perceived ease of 
getting to sleep, the duration of sleep, and the quality and 
depth of sleep. Less subject-reported WASO was obtained 
only after eszopiclone 3 mg. DSST scores were not signiﬁ  -
cantly different after nights 1, 15, and 29 relative to placebo. 
Somnolence and unpleasant taste were the most common 
treatment-related side-effects.
Thus the study by Zammit et al (2004) conﬁ  rms the 
hypnotic efﬁ  cacy of eszopiclone compared with placebo 
in non-elderly subjects with chronic primary insomnia. 
Eszopiclone reduced the stage 2 SOL and WASO whereas 
it increased the SE. Values corresponding to stage 2 were 
augmented, while slow wave sleep and REM sleep showed 
no signiﬁ  cant changes. Tolerance did not develop during the 
eszopiclone 3 mg administration period whereas rebound 
insomnia was present during the ﬁ  rst withdrawal night in 
the 2 mg group.
The efficacy and use of eszopiclone to improve 
sleep architecture over a longer period of time has also 
been evaluated (Krystal et al 2003; Zammit et al 2004). 
Observations were carried out at 70 sites and initially 
included 788 subjects with a mean age of 43.8 years 
suffering from chronic primary insomnia. However, 
the treatment was completed by only 471 subjects. 
The study was conducted according to a double-blind, 
placebo-controlled design with randomization. The 
efficacy of eszopiclone and of placebo was assessed 
once each week using an interactive voice response 
system. Eszopiclone signiﬁ  cantly reduced SOL, WASO, 
the number of awakenings per night, and the number of 
nocturnal awakenings per week, whereas total sleep time 
was increased compared with baseline at the end of the ﬁ  rst 
week (short-term efﬁ  cacy) and through months 1 to 6. Sleep 
quality, daytime ability to function, alertness, and physical 
well-being also improved signiﬁ  cantly. No signiﬁ  cant 
differences were observed in the placebo group. The 
type of side-effects encountered during active treatment 
(unpleasant taste, headache) corresponds well with what 
has been reported in previous studies.
In summary, during the active treatment period eszopi-
clone induced signiﬁ  cant improvements over baseline values 
in the population of subjects with chronic primary insomnia. 
Eszopiclone hypnotic activity was maintained throughout the 
6-month study period without any tolerance phenomena. 
Insomniac patients frequently take hypnotic medication 
for months or years despite the lack of information on their 
long-term effects. This applies not only to BZD hypnotics 
but also to most of the non-BZD derivatives. The ﬁ  nding that 
eszopiclone maintains its efﬁ  cacy over 6 months of nightly 
treatment gives scientiﬁ  c support for its clinical value in its 
long-term use. 
Roth et al (2005) evaluated the safety of eszopiclone during 
an additional 6-month period in subjects originally included 
in the study by Krystal et al (2003). The study was conducted 
open-label and comprised 471 non-elderly subjects with a di-
agnosis of chronic primary insomnia. In order to weekly assess 
sleep variables the study authors made use of an interactive 
voice response system. The evaluation was completed by only 
382 subjects (placebo: n = 86; eszopiclone 3 mg: n = 296). The 
sustained improvement in sleep and daytime function reported 
by Krystal et al (2003) during the double-blind phase of the 
investigation was conﬁ  rmed during the second 6-month phase 
of the study. Accordingly, the decrease of SOL, number of 
awakenings, and number of nights with one awakening, and 
the increase of TST and sleep quality remained signiﬁ  cantly 
different from baseline during the 6 months of open-label treat-
ment (Table 2b). There was no evidence of tolerance.Neuropsychiatric Disease and Treatment 2007:3(4) 449
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Chronic primary insomnia in elderly 
subjects
Sleep disturbance is very common among elderly people. 
Foley et al (1995) found that between 23% and 34% of sub-
jects aged 65 years and older have symptoms of primary or 
secondary insomnia.
Scharf et al (2005) and McCall et al (2006) assessed 
the effects of eszopiclone administration in elderly subjects 
with primary insomnia for a 2-week period. These were 
randomized, double-blind, placebo-controlled studies. Sub-
jects between the ages of 65 years and 86 years who met the 
DSM-IV deﬁ  nition for primary insomnia were included in 
the studies.
The study by Scharf et al (2005) comprised 231 subjects 
who were given either placebo or eszopiclone 1 mg or 2 mg 
nightly for 2 weeks. Efﬁ  cacy was assessed using an interac-
tive voice response system. Eszopiclone 2 mg was effective 
in reducing SOL and WASO while total sleep time was 
increased and sleep quality and depth, daytime alertness, 
and quality of life were improved compared with placebo 
(Table 2b). The number of awakenings per night was not 
signiﬁ  cantly different from placebo during the double-blind 
period. The efﬁ  cacy of eszopiclone 1 mg was limited to a 
reduction of SOL. Four side-effects were most frequently 
reported during eszopiclone 1 or 2 mg: headache, unpleas-
ant taste, somnolence, and dyspepsia. Tolerance was not 
observed during the study. 
The study by McCall et al (2006) included 255 subjects 
who received either eszopiclone 2 mg or placebo for 2 weeks. 
Efﬁ  cacy was assessed by means of PSG recordings and 
subjects’ reports. The subjects spent nights 1, 2, 13, and 
14 in the sleep laboratory and reported efﬁ  cacy measures 
during nights 1 to 14. The effects of eszopiclone 2 mg on 
sleep induction and maintenance are summarized in Table 
2b. Eszopiclone administration signiﬁ  cantly reduced latency 
to persistent sleep and WASO whereas TST and SE showed 
significant increments. The hypnotic drug significantly 
increased stage 2 sleep whereas stage 1, SWS (stages 3 and 
4), and REM sleep in min were not signiﬁ  cantly modiﬁ  ed. 
Subjective evaluation was relatively well correlated with the 
sleep laboratory ﬁ  ndings.
Insomnia coexisting with major 
depressive disorder
While both sleep and mood disorders share a commonal-
ity based on the underlying neurochemical cascades, sleep 
complaints are cardinal manifestations in patients with mood 
disorders. Such PSG characteristics include prolonged SOL 
and WASO, reduced TST and SE, and increased wakefulness. 
Assessment of sleep architecture shows that stage 1 sleep 
and REM sleep are increased whereas SWS and REM onset 
latency (REMOL) are reduced in a relatively small number of 
depressed patients. Although insomnia related to depression 
may be alleviated by treating the underlying mood disorder 
with antidepressant drugs (reviewed elsewhere, Jindal and 
Thase 2004); however, this is not always the case since a 
stimulant-like effect may appear during treatment. This 
is particularly true with the selective serotonin reuptake 
inhibitors (SSRIs), which according to pharmacoEEG studies 
behave as activating antidepressants (Oberndorfer et al 2000). 
Acute or subchronic administration of SSRIs to patients 
with major depression prolongs SOL, increases the number 
of awakenings and stage 1 sleep, and reduces TST and SE. 
Subjective evaluations indicate that the disruption of sleep 
continuity is more pronounced after ﬂ  uoxetine administration 
compared with the other SSRIs.
Recently, Fava et al (2006) evaluated the effect of adding 
eszopiclone to ﬂ  uoxetine in non-elderly patients who met 
DSM-IV criteria for MDD and comorbid insomnia. Patients 
who had been receiving ﬂ  uoxetine (dose range 20–40 mg/
day) were randomized to receive either eszopiclone 3 mg 
or placebo double-blind for 8 weeks. Patient self-reports of 
various sleep parameters, daytime functioning, and depressive 
symptoms were obtained with an interactive voice recording 
system. Sleep induction, sleep maintenance, and daytime 
function showed a signiﬁ  cant improvement in the patients 
in the eszopiclone plus ﬂ  uoxetine group compared with the 
placebo plus ﬂ  uoxetine group during the 8-week treatment 
period. In addition, scores on the Hamilton Depression-17 
Rating Scale were signiﬁ  cantly lower at week 4 and week 8. 
The treatment with eszopiclone was well tolerated and the 
type and frequency of side-effects were similar to those 
reported in subjects with chronic primary insomnia.
In summary, the co-administration of eszopiclone with 
ﬂ  uoxetine improved comorbid insomnia related to ﬂ  uoxetine 
administration and the psychiatric disease, without interfering 
with the SSRI antidepressant effect.
Insomnia during peri-menopause 
and early post-menopause
In another recent randomized controlled study, Soares 
and co-workers (2006) evaluated the efﬁ  cacy of 3 mg of 
eszopiclone for the treatment of insomnia in perimenopausal 
and early postmenopausal women (n = 410; aged 40–60 years Neuropsychiatric Disease and Treatment 2007:3(4) 450
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old). The study concluded with the ﬁ  nding that eszopiclone 
signiﬁ  cantly improved many sleep characteristics (sleep induc-
tion, maintenance, duration, quality, and next day functioning). 
The study also showed a positive impact on the mood, quality 
of life (QoL), and other subjective menopausal-related symp-
toms in post-menopausal women with insomnia.
Comparison of zopiclone 
with placebo and benzodiazepine 
hypnotics
There are no published trials that compare eszopiclone with 
other hypnotic drugs. On the other hand, zopiclone has been 
extensively compared not only with placebo but also with 
benzodiazepine hypnotics in subjects with chronic insomnia. 
However, none of the studies used neither systematic nor 
objective scaling methods for classifying sleep disturbance 
(ie, DSM-IV or ICSD). Moreover, in most trials there was no 
adherence to a strict double-blind placebo-controlled design, 
nor in most cases were attempts made to combine subjective 
assessments with objective PSG measures for evaluating 
sleep and daytime impairment. 
In studies comparing zopiclone 7.5 mg with placebo in 
patients with chronic insomnia the active drug was found 
to reduce both SOL and the number of awakenings, and to 
increase TST and sleep quality (Duriez et al 1979; Chaudoir 
et al 1983; Mamelak et al 1983; Beaumont and Holland 
1990; Pecknold et al 1990). In addition, zopiclone decreased 
stage 1 sleep, increased stage 2 sleep, reduced or had no 
effect on stages 3 and 4, and did not signiﬁ  cantly modify 
the duration of REM sleep. There was no rebound insomnia 
upon drug withdrawal (Mamelak et al 1983; Pecknold 
et al 1990). The potential for tolerance was assessed in two 
studies where subjects with chronic insomnia received zopiclone 
7.5 mg/day for 8 and 17 weeks, respectively. In all of the studies 
no signiﬁ  cant evidence was found for tolerance to the effects of 
zopiclone (Fleming et al 1988; Pecknold et al 1990).
A number of trials have compared the hypnotic effects 
of zopiclone with the long-acting (ﬂ  urazepam, nitrazepam), 
intermediate-acting (ﬂ  unitrazepam, temazepam), and short-
acting (triazolam, midazolam) benzodiazepine hypnotics. 
In this respect it has been found that zopiclone 7.5 mg, ﬂ  u-
razepam 30 mg, and nitrazepam 5 mg have similar overall 
hypnotic efﬁ  cacy in adult patients with chronic insomnia 
(Petre Quadens et al 1983; Tamminen and Hansen 1987). 
In addition, the active agents were signiﬁ  cantly better than 
placebo according to clinicians’ and/or subjects’ global 
impressions (Anderson 1987; Ponciano et al 1990). Daytime 
sedation was more likely to occur after ﬂ  urazepam or nitraz-
epam administration.
It was initially established by Wickstrom et al (1983) 
that zopiclone 7.5 mg and ﬂ  unitrazepam 2 mg improve to an 
almost similar extent sleep induction, sleep maintenance, and 
condition in the morning of insomniac subjects. Hajak et al 
(1994) also compared zopiclone 7.5 mg with ﬂ  unitrazepam 
1 mg and placebo in subjects suffering from insomnia. The 
treatments were given for 28 nights. Zopiclone signiﬁ  cantly 
reduced the SOL and the number of nocturnal awakenings, 
and increased the TST compared with placebo. Daytime well-
being was also improved. In contrast, the response rate in 
the ﬂ  unitrazepam 1 mg group was not signiﬁ  cantly different 
from that of placebo.
Zopiclone 7.5 mg has been compared also with temaze-
pam 20 mg in subjects with chronic insomnia. The results 
of the studies have shown that zopiclone and temazepam 
are almost equally effective with respect to sleep induction, 
sleep maintenance, and quality of sleep (Wheatley 1985; van 
der Kleijn 1989).
Comparisons of the hypnotic effects of zopiclone and 
triazolam have produced consistent results. Hajak et al 
(1994) compared zopiclone 7.5 mg against triazolam 0.25 
mg, and placebo in private practice patients with insomnia. 
Zopiclone was signiﬁ  cantly more effective than placebo in 
improving sleep induction and sleep maintenance, while no 
such difference occurred with the benzodiazepine derivative. 
Further, Autret et al (1987) found that zopiclone 7.5 mg was 
signiﬁ  cantly superior to triazolam 0.5 mg for improving sleep 
quality in subjects with chronic insomnia.
Begg et al (1992) compared the efﬁ  cacy (based on 
LSEQ) and tolerance of zopiclone 7.5 mg and midazolam 
15 mg in subjects with sleep disorders (n = 88; 18+ years 
old). The authors concluded that the zopiclone daily 
improved all items on the LSEQ than daily administration 
of midazolam but was associated with signiﬁ  cant rebound 
insomnia. Notwithstanding this, there were no signiﬁ  cant 
differences between the hypnotic drugs in comparisons 
between groups.
Adverse events
Table 3 shows the incidence of treatment-emergent adverse 
events in non-elderly subjects who received eszopiclone 
3 mg for 44 nights, and elderly patients who were given the 
hypnotic agent at a dose of 2 mg for 14 nights. The most 
commonly reported side-effect was unpleasant or bitter taste 
followed by headache, dyspepsia, pain, diarrhea, dry mouth, 
dizziness, and accidental injury.Neuropsychiatric Disease and Treatment 2007:3(4) 451
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Dosage and administration
The recommended starting dose of eszopiclone for 
non-elderly insomniac patients is 2 mg. If necessary the 
amount of drug can be increased to 3 mg. Elderly patients 
should receive initially 1 mg eszopiclone immediately before 
bedtime. The dose can be increased to 2 mg if difﬁ  culty 
staying asleep is not satisfactorily resolved.
Taking into account that the metabolic clearance of 
eszopiclone is impaired in patients with severe hepatic insuf-
ﬁ  ciency, its administration is to be avoided; alternatively, a 
dose of no greater than 1 mg can be administered, but with 
close monitoring.
Rebound insomnia
Rebound insomnia following withdrawal of eszopiclone has 
been examined only in the study by Zammit et al (2004). 
Discontinuation of the active treatment with 2 mg was fol-
lowed by a signiﬁ  cant increase of WASO and a reduction 
of sleep efﬁ  ciency on the ﬁ  rst night of withdrawal compared 
with baseline. Following cessation of eszopiclone 3 mg there 
was no signiﬁ  cant rebound on the ﬁ  rst or the second night 
after discontinuation. 
Of note, withdrawal of zopiclone 7.5 mg was followed 
by mild (Lader and Frcka 1987; Fleming et al 1990) or no 
rebound insomnia (Jovanovic and Dreyfus 1983; Mamelak 
et al 1983; Petre Quadens et al 1983; Tiberge et al 1988) in 
patients with chronic insomnia.
Tolerance
Based on the available clinical evidence, eszopiclone is gen-
erally well tolerated. In the randomized controlled study of 
Soares et al (2006), no evidence of tolerance to eszopiclone 
over the 4-week study period was noted. In other studies on 
the long-term effects of eszopiclone use, Krystal et al (2003) 
and Roth et al (2005) found that, at the 3 mg dose level, the 
drug showed no evidence of producing tolerance effects after 
6 and 12 months of administration. Interestingly, in several 
studies where zopiclone was administered over periods of up 
to 17 weeks, the activity of the hypnotic drug was maintained 
throughout the whole treatment period (Hindmarch 1990).
Memory impairment
Impairment of short-term memory is a particularly undesir-
able effect of the BZD hypnotics. The possibility of such 
impairment of memory with eszopiclone has been investi-
gated in comparison with placebo. 
In a study designed to determine the long-term effects of 
eszopiclone 3 mg in 595 adult subjects with chronic primary 
insomnia, memory impairment occurred in 1.3% of subjects 
(Krystal et al 2003). Furthermore, in a 6-week study in non-
elderly subjects of nightly administered placebo (n = 99), 
eszopiclone 2 mg (n = 104), or 3 mg (n = 105), the rates for 
memory impairment were 1%, 1%, and 0%, respectively 
(Zammit et al 2004).
It should be noted that in volunteers tested 1 hour after 
zopiclone 7.5 mg administration, short-term memory pro-
cesses were impaired, as evidenced by signiﬁ  cant decrements 
in visual memory, digit learning, and reaction time. On the 
other hand, long-term memory assessed 10 and 24 hours after 
zopiclone administration had already regained placebo levels 
(Fossen et al 1983; Subhan and Hindmarch 1984; Harrison 
et al 1985; Grifﬁ  ths et al 1986; Warot et al 1987).
Table 3 Dosage, onset of action and adverse events of eszopiclone in non-elderly and elderly subjects with chronic primary insomnia
 Non-elderly  subjectsa Elderly  subjectsb
Dosage (mg)  2–3  1–2
Onset of action (h)  0.5–1  0.5–1 
Adverse events  unpleasant taste  headache
  viral infection  urinary tract infection
 headache  unpleasant  taste
 somnolence  dry  mouth
 dry  mouth  dizziness
 dizziness  pain
 dyspepsia  accidental  injury
 nausea  diarrhea
 rash  nervousness
 anxiety  neuralgia
 respiratory  infection 
 confusion
aNon-elderly subjects: 3 mg – n = 106
bElderly subjects: 2 mg – n = 215Neuropsychiatric Disease and Treatment 2007:3(4) 452
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Withdrawal symptoms, abuse 
and dependence
In the 6-week study of Zammit et al (2004) in elderly subjects, 
single blind placebo was administered on the ﬁ  rst 2 nights 
of discontinuation. New adverse events were recorded dur-
ing the withdrawal period beginning with day 45, up to 14 
days after discontinuation. Withdrawal symptoms reported 
by 1.0% and 2.9% of subjects taking eszopiclone 2 and 3 mg, 
respectively, comprised anxiety, abnormal dreams, hyper-
esthesia, nausea, and upset stomach. This ﬁ  nding warrants 
further investigation to determine whether progressive 
eszopiclone dosage reduction is necessary.
There is no evidence of the addicting potential of eszopi-
clone in individuals without known histories of drug abuse. 
In an unpublished report that refers to patients with known 
dependence for BZDs, eszopiclone at doses of 6 and 12 mg 
produced euphoria effects similar to those of diazepam 20 mg 
(Scharf 2006). The reinforcing properties of eszopiclone 
compared with BZDs in drug addicts justiﬁ  es its classiﬁ  cation 
as a Schedule IV controlled substance in the United States.
Acknowledgments
The authors sincerely acknowledge the enthusiastic and 
constructive comments of the anonymous reviewers on the 
earlier draft of this manuscript. Their comments helped us 
greatly to improve the ﬁ  nal version of this manuscript.
Disclosures
The authors declare that they have no proprietary, ﬁ  nancial, 
professional, or any other personal interest of any nature or kind 
in any product or services and/or company that could be con-
structed or considered a potential conﬂ  ict of interest that might 
have inﬂ  uenced the views expressed in this manuscript.
References
[APA] American Psychiatric Association. 1994. Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV). Washington DC: APA.
Anderson AA. 1987. Zopiclone and nitrazepam:a multicenter placebo 
controlled comparative study of efﬁ  cacy and tolerance in insomniac 
patients in general practice. Sleep, 10 (Suppl 1):54–62.
Ator NA, McCann UD. 2005. New insights into the GABAA receptor. CNS 
Spectrums, 10:20.
Autret E, Maillard F, Autret A. 1987. Comparison of the clinical hypnotic 
effects of zopiclone and triazolam. Eur J Clin Pharmacol, 31:621–3.
Bardone MC, Ducrot R, Garret C, et al. 1978. Benzodiazepine-like central 
effects of RP 27267, a dihidro-7-oxo-5H-pyrrolo[3,4-b]pyrazine 
derivative. Int Congr Pharmacology, Abstract No. 2319. London: 
Pergamon Press.
Beaumont G, Holland RL. 1990. A multi-centre open study in general 
practice to evaluate the efﬁ  cacy and acceptability of zopiclone 7.5 mg 
nocte in patients requiring the prescription of a hypnotic. Int Clin 
Psychopharmacol, 5 (Suppl 2):11–20.
Becquemont L, Mouajjah S, Escaffre O, et al. 1999. Cytochrome P-450 
3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab 
Dispos, 27:1068–73.
Begg EJ, Robson RA, Frampton CM, et al. 1992. A comparison of efﬁ  cacy 
and tolerance of the short acting sedatives midazolam and zopiclone. 
NZ Med J, 105:428–9.
Buysee D, Reynolds C, Kupfer D, et al. 1994. Clinical diagnoses of 216 in-
somnia patients using the International Classiﬁ  cation of Sleep Disorders 
(ICSD), DSM-IV and ICD-10 categories: a report from the APA/NIMH 
DSM-IV ﬁ  eld trial. Sleep, 17:630–7.
Chaudoir PJ, Jarvie MB, Wilcox GJ. 1983. The acceptability of a non-
benzodiazepine hypnotic (zopiclone) in general practice. J Int Med 
Res, 11:333–7.
Carlson JN, Haskew R, Wacker J, et al. 2001. Sedative and anxiolytic 
effects of zopiclone´s enantiomers and metabolite. Eur J Pharmacol, 
415:181–9.
Coleman R, Roffwarg H, Kennedy S, et al. 1981. Sleep-wake disorders based 
on a polysomnographic diagnosis. JAMA, 247:997–1003.
Depoortere H, Decobert M, Granger P, et al. 1986. Hypnotics:clinical value 
of pharmaco-EEG methods. Neuropsychobiology, 16:157–62.
Doble A. 1999. New insights into the mechanism of action of hypnotics. 
J Psychopharmacol, 13:S11–20.
Drover DR. 2004. Comparative pharmacokinetics and pharmacodynamics 
of short-acting hypnosedatives. Clin Pharmacokinet, 43:227–38.
Duriez R, Barthélémy CI, Rives H, et al. 1979. Traitement des troubles 
du sommeil par la zopiclone. Essais cliniques en double insu contre 
placébo. Thérapie, 34:317–25.
Ebert B, Wafford KA, Deacon S. 2006. Treating insomnia:current and investi-
gational pharmacological approaches. Pharmacol Ther, 112:612–29.
Fava M, McCall W, Krystal A, et al. 2006. Eszopiclone co-administered with 
ﬂ  uoxetine in patients with insomnia coexisting with major depressive 
disorder. Biol Psychiatry, 59:1052–60.
Fernández C, Maradeix V, Gimenez F, et al. 1993. Pharmacokinetics of 
zopiclone and its enantiomers in Caucasian young healthy volunteers. 
Drug Metab Dispos, 21:1125–8.
Fernández C, Martin C, Gimenez F, et al. 1995. Clinical pharmacokinetics 
of zopiclone. Clin Pharmacokinet, 29:431–41.
Fleming JA, Bourgouin J, Hamilton P. 1988. A sleep laboratory evaluation 
of the long-term efﬁ  cacy of zopiclone. Can J Psychiatry, 33:103–7.
Fleming JA, McClure DJ, Mayes C, et al. 1990. A comparison of the efﬁ  cacy, 
safety and withdrawal effects of zopiclone and triazolam in the treatment 
of insomnia. Int Clin Psychopharmacol, 5 (Suppl 2):29–37.
Foley DJ, Monjan AA, Brown SL, et al. 1995. Sleep complaints among 
elderly persons:an epidemiologic study of three communities. Sleep, 
18:425–32.
Fossen A, Godlibsen OB, Loyning Y, et al. 1983. Effects of hypnotics on 
memory. Pharmacology, 27 (Suppl 2):116–26.
Grifﬁ  ths AN, Jones DM, Richens A. 1986. Zopiclone produces effects on 
human performance similar to ﬂ  urazepam, lormetazepam and triazolam. 
Br J Clin Pharmacol, 21:647–53.
Hajak G, Clarenbach P, Fischer W, et al. 1994. Zopiclone improves sleep 
quality and daytime well-being in insomniac patients: comparison 
with triazolam, ﬂ  unitrazepam and placebo. Int Clin Psychopharmacol, 
9:251–61.
Harrison C, Zubhan Z, Hindmarch I. 1985. Residual effects of zopiclone 
and benzodiazepine hypnotics on psychomotor performance related to 
car driving. Drugs Exp Clin Res, 11:823–9.
Harvey SC. 1980. Hypnotics and sedatives. In Goodman Gilman 
A, Goodman LS, Gilman A (eds). The pharmacological basis of thera-
peutics. 6th ed. New York: MacMillan. p. 339–76.
Hindmarch I. 1990. Immediate and overnight effects of zopiclone 7.5 
mg and nitrazepam 5 mg with ethanol, on psychomotor performance 
and memory in healthy volunteers. Int Clin Psychopharmacol, 5 
(Suppl 2):105–13.
International Classiﬁ  cation of Sleep Disorders: Diagnostic and Coding 
Manual. 2005. 2nd ed. Westchester: American Academy of Sleep 
Medicine.Neuropsychiatric Disease and Treatment 2007:3(4) 453
Eszopiclone and insomnia
Jindal RD, Thase ME. 2004. Treatment of insomnia associated with clinical 
depression. Sleep Med Rev, 8:19–30.
Jovanovic UJ, Dreyfus JF. 1983. Polygraphical sleep recordings in 
insomniac patients under zopiclone or nitrazepam. Pharmacology, 27 
(Suppl 2):136–45.
Julou L, Bardone MC, Blanchard JC, et al. 1983. Pharmacological studies 
on zopiclone. Pharmacology, 27 (Suppl 2):46–58.
Julou L, Blanchard JC, Dreyfus JF. 1985. Pharmacological and clinical 
studies of cyclopyrrolones:Zopiclone and suriclone. Pharmacol 
Biochem Behav, 23:653–59.
Korpi ER. 2006. GABAA receptor subtypes in sedation and hypnosis. In 
Lader M, Cardinali DP, Pandi-Perumal SR (eds). Sleep and sleep 
disorders: a neuropsychopharmacological approach. Texas and New 
York, USA: Landes Bioscience/Eurekah.com and Springer Science + 
Business Media, Inc., pp. 3–9.
Koshorek G, Roehrs T, Sicklesteel J, et al. 1988. Dose effects of zolpidem 
on transient insomnia. Sleep Res, 17:47.
Krystal AD, Walsh JK, Laska E, et al. 2003. Sustained efﬁ  cacy of eszopi-
clone over 6 months of nightly treatment:Results of a randomized, 
double-blind, placebo-controlled study in adults with chronic insomnia. 
Sleep, 26:793–9.
Lader M, Frcka G. 1987. Subjective effects during administration and 
on discontinuation of zopiclone and temazepam in normal subjects. 
Pharmacopsychiatry, 20:67–71.
Lichstein KL. 2000. Secondary insomnia. In Lichstein KL, Morin CM 
(eds). Treatment of late-life insomnia. London: Sage Publications. 
p. 297–319.
Lichstein KL, Gellis LA, Stone KC, et al. 2006. Primary and Secondary 
Insomnia. In. Clinical Pharmacology of Sleep, S.R. Pandi-Perumal and 
J.M. Monti (eds.), pp. 1–9. Basel, Switzerland: Birkhauser Verlag.
Mamelak M, Scima A, Price V. 1983. Effects of zopiclone on the sleep of 
chronic insomniacs. Pharmacology, 27(Suppl 2):156–64.
McCall WV, Erman M, Krystal AD et al. 2006. A polysomnographic study 
of eszopiclone in elderly patients with insomnia. Curr Med Res Opin, 
22:1633–42.
Momose T. 1983. Effectiveness of zopiclone as a preoperative hypnotic. 
Pharmacology, 27(Suppl 2):196–204.
Monti JM. 2004. Primary and secondary insomnia:Prevalence, causes and 
current therapeutics. Curr Med Chem – CNS Agents, 4:119–37.
Monti JM, Boussard M, Olivera S, et al. 1993. The effect of midazolam on 
transient insomnia. Eur J Clin Pharmacol, 44:525–7.
Monti JM, Monti D. 2006. Overview of currently available benzodiazepine 
and nonbenzodiazepine hypnotics. In Pandi-Perumal SR, Monti JM 
(eds). Clinical Pharmacology of Sleep. Basel: Birkhäuser. p. 207–23.
Moon CAL, Hindmarch I, Holland, RL. 1990. The effect of zopiclone 
7.5 mg on the sleep, mood and performance of shift workers. Int Clin 
Psychopharmacol, 5(Suppl):79–83.
Najib J. 2006. Eszopiclone, a nonbenzodiazepine sedative-hypnotic 
agent for the treatment of transient and chronic insomnia. Clin Ther, 
28:491–516.
Nicholson AN, Stone BM. 1983. Zopiclone:Sleep and performance studies 
in healthy man. In Nicholson AN, Schlosberg A, Dreyfus JF (eds). 
Zopiclone:A Third Generation of Hypnotics. Basel:Karger. p. 92–7.
Noble S, Langtry HD, Lamb HM. 1998. Zopiclone:An update of its pharma-
cology, clinical efﬁ  cacy and tolerability in the treatment of insomnia. 
Drugs, 55:277–302.
Oberndorfer S, Saletu-Zyhlarz G, Saletu B. 2000. Effects of selective 
serotonin reuptake inhibitors on objective and subjective sleep quality. 
Neuropsychobiology, 42:69–81.
Pecknold J, Wilson R, Le Morvan P. 1990. Long-term efﬁ  cacy and with-
drawal of zopiclone:a sleep laboratory study. Int Clin Psychopharmacol, 
5(Suppl 2):57–67.
Petre Quadens O, Hoffman G, Buytaert G. 1983. Effects of zopiclone 
as compared to ﬂ  urazepam on sleep in women over 40 years of age. 
Pharmacology, 27(Suppl 2):146–155.
Ponciano E, Freitas F, Camara J, et al.1990. A comparison of the 
efﬁ  cacy, tolerance and residual effects of zopiclone, ﬂ  urazepam 
and placebo in insomniac outpatients. Int Clin Psychopharmacol, 5 
(Suppl 2):69–77.
Rosenberg R, Caron J, Roth T, et al. 2005. An assessment of the efﬁ  cacy and 
safety of eszopiclone in the treatment of transient insomnia in healthy 
adults. Sleep Med, 6:15–22.
Roth T, Walsh JK, Krystal A, et al. 2005. An evaluation of the efﬁ  cacy and 
safety of eszopiclone over 12 months in patients with chronic primary 
insomnia. Sleep Med, 6:487–95.
Sanger DJ. 2004. The pharmacology and mechanisms of action of new 
generation, non-benzodiazepine hypnotic agents. CNS Drugs, 18 
(Suppl 1):9–15.
Scharf M. 2006. Eszopiclone for the treatment of insomnia. Expert Opin 
Pharmacother, 7:345–356.
Scharf M, Erman M, Rosenberg R, et al. 2005. A 2-week efﬁ  cacy and 
safety study of eszopiclone in elderly patients with primary insomnia. 
Sleep, 28:720–7.
Soares CN, Joffe H, Rubens R, et al. 2006. Eszopiclone in patients with 
insomnia during perimenopause and early postmenopause: a random-
ized controlled trial. Obstet Gynecol, 108:1402–10.
Subhan Z, Hindmarch I. 1984. Effects of zopiclone and benzodiazepine 
hypnotics on search in short-term memory. Neuropsychobiology, 
12:244–8.
Tamminen T, Hansen PP. 1987. Chronic administration of zopiclone and 
nitrazepam in the treatment of insomnia. Sleep, 10(Suppl 1):63–72.
Tiberge M, Calvet V, Khayi N, et al. 1988. Comparison des effets de la 
zopiclone et du triazolam sur le sommeil du sujet sain. Encéphale, 
14:319–324.
Ueki S, Watanabe S, Yamamoto T, et al. 1987. Behavioral and electroen-
cephalographic effects of zopiclone, a cyclopyrrolone derivative. Japan 
J Pharmacol, 43:309–26.
Van der Kleijn E. 1989. Effects of zopiclone and temazepam on sleep, 
behavior and mood during the day. Eur J Clin Pharmacol, 36:247–51.
McCall WV, Erman M, Krystal AD, et al. 2006. A polysomnography study 
of eszopiclone in elderly patients with insomnia. Curr Medical Res 
Opin, 22:1633–42.
Warot D, Bensimon G, Danjou P, et al. 1987. Comparative effects of 
zopiclone, triazolam and placebo on memory and psychomotor 
performance in healthy volunteers. Fund Clin Pharmacol, 1:145–52.
Wheatley D. 1985. Zopiclone:A non-benzodiazepine hypnotic. Controlled 
comparison to temazepam insomnia. Br J Psychiatry, 146:312–4.
Wickstrom E, Barbo SE, Dreyfus JF, et al. 1983. A comparative study of 
zopiclone and ﬂ  unitrazepam in insomniacs seen by general practitioners. 
Pharmacology, 27(Suppl 2):165–72.
Zammit GK, McNabb LJ, Caron J, et al. 2004. Efﬁ  cacy and safety of 
eszopiclone across 6-weeks of treatment for primary insomnia. Curr 
Med Res Opin, 20:1979–91.